Strategic Advisory Board
Strategic Advisory board role is to provide a support for the transition from Drug Discovery Stage Company through to PreClinical and Clinical Development. OriBase Pharma decided to create this international board by including members based on following criteria:
- BigPharma and/or Start-up experience
- Venture financing and growth experience
- In-Licensing / Out Licensing Experience
- Biotech & Diagnostics experience
- Visionary people
- Complementary background
- Ability to provide strong input and challenge very constructively main strategic decisions
Jean Louis Roux Dit Buisson, MSc, MBA Managing Director - Foroventure
Jean-Louis has 25 years of experience in developing and growing technology based companies covering materials and processes and health care industries.Jean-Louis has held responsibilities as CEO, M&A, Finance, Marketing, Sales, R&D management and Production in large groups, start-ups and SMEs. Jean-Louis holds an MBA from Insead, an MSc in Chemical Engineering from MIT and an Engineering degree from ENSCP Paris-Tech.
Dr Abderahim Lachgar, PhD, MBA, COO Invectys, Paris
Dr Lachgar made his academic program in the National institute of Blood transfusion and the University of Pierre et Marie Curie. Further to his doctorate in immunovirology, he contributed to the creation and to the development of Neovacs company, where he was in charge of the programs of immuno-modulation and immunotherapy. He participated in various European clinical developments trials. He acquired a strong expertise in prospective research valuation as well as in industrial prospective of the innovation through his Master degree in the CNAM and ENSAM. He is the founder of Biosphere Consulting to accompany project leaders, academic institutions as well as international organizations in the field of the valuation of the innovation and the cooperation.
Michel Azoulay, MD, MBA, CEO Biotech MedPartners
Dr. Michel Azoulay leads Biotech MedPartners, an international consulting firm.
He has over 20 years of business and scientific experience in the pharmaceutical industry. Throughout his career he specialized in strategic analysis, planning, due diligence, valuation and business development.
Michel was the Oncology leader and Engagement manager for IMS Health and has a broad range of experience in consulting services for more than fifteen years and has managed over 100 consulting engagements. Prior to IMS, Dr. Azoulay had a successful career at Amgen in Europe, where he has worked for nine years in strategic development of oncology drugs and business management.
Michel holds an MBA with high honors from ESCP and earned his MD from Montpellier University School of Medicine, France.
Roman Drhovský M&A Manager at PPF
Roman Drhovsky has over 20 years of experience in M&A, corporate finance, investment banking and corporate governance where he has completed dozens of transactions in multiple industries and regions with focus on biotechnology over the last years. He is M&A Manager of PPF a.s., previously served as Head of Corporate Finance of PPF Bank, Partner of Celestis Finance, Senior Officer of Credit Lyonnais Prague and held several board position in financial and industrial companies. Roman graduated with honors from Prague School of Economics.